Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vaccine committee votes to scrap universal hepatitis B shots for newborns despite outcry from children’s health experts - 2Poland open to German troops to help secure Ukraine ceasefire
- 3Step by step instructions to Show Children the Significance of Appropriate Handshaking
- 4Discovering a true sense of harmony: Contemplation and Care Practices
- 5Iran denies launching ballistic missiles towards Kurdistan region of Iraq
- Bolsonaro says hallucinatory effects of meds made him tamper with ankle tag
- Find the Insider facts of Viable Advertising: Building a Positive Brand Picture
- Between 600 to 800 aid trucks entering Gaza daily since start of ceasefire, COGAT confirms
- Which restaurants and fast food chains will be open on Christmas Eve and Christmas Day?
- Figure out How to Acquire Rewarding Open Record Rewards
- The Job of Attorneys: It is Important to Comprehend When Legitimate Help
- Roman around the Christmas tree | Space photo of the day for Dec. 25, 2025
- Forum Dvorah demands clear support for women in combat as IDF gender debate escalates
- Independence from the rat race for Recent college grads: Systems and Tips
